News articles about Biostar Pharmaceuticals (NASDAQ:BSPM) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biostar Pharmaceuticals earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.1091193270698 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Biostar Pharmaceuticals (NASDAQ:BSPM) traded up $0.11 during midday trading on Friday, reaching $2.01. 253,700 shares of the company’s stock were exchanged, compared to its average volume of 95,967. The company has a market cap of $5.01, a P/E ratio of 2.87 and a beta of 1.87. Biostar Pharmaceuticals has a one year low of $1.18 and a one year high of $4.30.
Biostar Pharmaceuticals (NASDAQ:BSPM) last posted its earnings results on Wednesday, November 15th. The company reported ($0.50) earnings per share for the quarter. During the same period in the previous year, the company posted ($3.12) EPS.
About Biostar Pharmaceuticals
Biostar Pharmaceuticals, Inc (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co, Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China).
Receive News & Ratings for Biostar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.